A meta-analysis examined data from 459 patients with heart failure with reduced ejection fraction. The researchers compared the drug Cimlanod against a placebo to see if it improved survival or heart function. The study looked at cardiovascular mortality, hemodynamic measures, and severe adverse events. The analysis also checked all-cause mortality, cardiac death, and various blood pressure and heart rate readings.
The results showed that Cimlanod did not significantly reduce the risk of death from any cause. It also did not significantly reduce cardiac death or serious adverse events. However, the drug did significantly increase the risk of symptomatic hypotension, which is low blood pressure that causes symptoms. Patients taking the highest dose also saw a significant drop in systolic blood pressure.
The study noted a modest improvement in cardiac index, a measure of heart pumping ability. Despite these mixed findings, the evidence does not currently support routine clinical use of this medication. Further studies are required to identify whether any specific subgroup may benefit from the treatment.